Stantec reports second quarter 2025 results, delivering over 20% growth in adjusted earnings per share and increases its 2025 outlook
Net revenue of $1.6 billion, an increase of 6.9% compared to Q2 2024
Adjusted EBITDA1 increase of 15.0% to $284.4 million and adjusted EBITDA margin1 of 17.8%, a 120 basis point increase over Q2 2024
Diluted EPS of $1.19 and adjusted EPS1 of $1.36, up 63.0% and 21.4%, respectively, compared to Q2 2024
Contract backlog of $7.9 billion, up 9.9% year-over-year, including 9% organic growth
Acquired Cosgroves, a 90-person industry-leading firm, expanding buildings engineering capabilities in New Zealand
Closed the acquisition of Page, a 1,400 person US-based design, architecture and engineering firm
Increased guidance for net revenue, EBITDA margin, adjusted diluted EPS and adjusted ROIC to reflect strong performance year-to-date and the closure of the Page acquisition.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Sun
10 minutes ago
- Toronto Sun
Werner recalls more than 100,000 ladders due to potential fall and injury hazard
Published Aug 14, 2025 • 1 minute read This image provided by U.S. Consumer Product Safety Commission shows Werner Multi-Max Pro Multi-Purpose Ladder that the company is recalling more than 100,000 faulty ladders due to a locking mechanism that can fail, potentially causing users to fall and injure themselves on Thursday, Aug. 14, 2025. (U.S. Consumer Product Safety Commission via AP) AP Werner on Thursday said it is recalling more than 100,000 faulty ladders due to a locking mechanism that can fail, potentially causing users to fall and injure themselves. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account In cooperation with federal consumer product regulators, Werner is recalling 122,250 Multi-Max Pro ladders that come in 20-foot and 24-foot sizes. The ladders were sold exclusively at Home Depot between November 2021 and February 2024 with prices between $200 and $281. The Illinois-based company said owners of the ladders being recalled should stop using them immediately and register at to begin the process for a full refund. Once owners have properly disposed of their ladders per Werner's instructions, the company said it will issue a check for a full refund. The ladders are silver with a blue top and a blue label on the side rail with an oval containing the word 'Werner' and 'MULTI MAX PRO.' The size and model numbers are ALMP-20IAA or ALMP-24IAA and have a long black rope in the back. This advertisement has not loaded yet, but your article continues below. Werner said it has received 18 reports of falls, including 14 reports of injuries resulting in bruising, lacerations, head injuries and fractures to the wrist, leg and ribs. If consumers think they own a ladder being recalled, they can call Werner at 888-624-1907 from 8:30 a.m. to 6 p.m. Eastern time Monday through Friday or email ladder↕ More information can be found online at or by clicking on 'Recalls' at the bottom of Werner's home page. The recall number is 25-431. Werner noted that models ALMP-16IAA and ALMP-18IAA Multi-Max Pro Ladders currently offered for sale have a different design and are not included in the recall. Sunshine Girls Sunshine Girls World Columnists Toronto & GTA
Cision Canada
40 minutes ago
- Cision Canada
Biotech Stocks Rally as Oncology Market Targets $866B by 2034
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /CNW/ -- Equity Insider News Commentary – Despite alarming federal budget cuts that stand to potentially harm the national battle against cancer, it appears that the private sector continues to step up, with hundreds of millions of VC dollars pouring into oncology ventures so far in 2025. While there has been a recent victory in the Senate to restore $15 million for the Pancreatic Cancer Research Program (PCARP), the prior elimination of the only federal program dedicated solely to researching pancreatic cancer served as a stark reminder of these ongoing funding challenges. This dynamic is setting the stage for a "flight to quality" among investors, who are now more than ever looking for innovative leaders with strong pipelines and clear paths to regulatory execution, a key milestone that can separate a promising biotech from a potential breakthrough like Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), ProPhase Labs, Inc. (NASDAQ: PRPH), IO Biotech, Inc. (NASDAQ: IOBT), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), and PDS Biotechnology Corporation (NASDAQ: PDSB). According to a report from Global Market Insights, the global oncology market was estimated at US$345.1 billion in 2025, and while growing at an impressive 10.8% CAGR, is projected to reach US$866.1 billion by 2034 — with $377.1 billion of that coming from the USA alone. Even more optimistic is a report from Vision Research Reports, which sees the global cancer drug sector surpassing US$900 billion in sales by 2034. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has officially entered the most critical phase of its development journey—pursuing a potential registration-enabling trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for its flagship asset, pelareorep. In its latest Q2 2025 report, the company confirmed it has begun formal discussions with the U.S. Food and Drug Administration (FDA) aimed at finalizing a pivotal study design, with trial start-up activities expected to begin as early as Q4 2025. For investors and potential partners, this represents a clear transition from promising clinical data to potential regulatory approval in one of medicine's most challenging cancer types. "We have turned the corner from proof-of-concept studies and will be sprinting toward regulatory clarity for the remainder of the year," said Jared Kelly, CEO of Oncolytics. "As we shore up our intellectual property, get a clear registration path for pelareorep, and allow our GOBLET data to mature, we will establish our position as the only platform immunotherapy in gastrointestinal tumors." The strategic focus on mPDAC reflects both compelling clinical results and a significant market opportunity. Pelareorep is a systemically delivered oncolytic virus designed to convert immunologically "cold" tumors—those typically invisible to the immune system—into "hot" tumors that can respond to immunotherapy. In first-line pancreatic cancer studies, pelareorep-based regimens have demonstrated a notable 21.9% two-year overall survival rate, compared to a 9.2% historical benchmark for standard chemotherapy alone. Even more compelling, when pelareorep was combined with chemotherapy and a checkpoint inhibitor, researchers recorded a 62% objective response rate—particularly significant given that checkpoint inhibitors are not currently approved for use in this indication. These results stem from pelareorep's dual mechanism: it both replicates within cancer cells and activates the body's immune response against tumors. "This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action," said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. "We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME—all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep." Translational data from the GOBLET and AWARE-1 studies demonstrate how pelareorep transforms the tumor microenvironment, increasing PD-L1 expression, heightening interferon signaling, and mobilizing tumor-infiltrating lymphocytes in the blood—changes that correlate with tumor size reduction. This mechanistic validation, combined with survival data from over 1,100 patients across multiple studies, has solidified the company's decision to prioritize this indication. Oncolytics' execution-focused strategy is being led by Jared Kelly and Andrew Aromando, who both played key roles in Ambrx Biopharma's US$2 billion acquisition by Johnson & Johnson. Kelly was appointed CEO earlier this year, while Aromando recently joined as Chief Business Officer. In line with their focus on capital efficiency, the company has terminated its At-the-Market and Equity Line of Credit facilities, citing sufficient resources to advance key milestones without near-term shareholder dilution. Regulatory advantages are already in place to accelerate development. Pelareorep holds Fast Track and Orphan Drug designations for pancreatic cancer from the FDA, meaning the agency has already recognized both the drug's potential and the serious unmet need in this patient population. These statuses streamline review processes and enhance the program's attractiveness to potential pharmaceutical partners. The context underscores the opportunity: pancreatic cancer remains one of the deadliest common cancers, with a five-year survival rate of less than 14%. Unlike other cancers where immunotherapies have transformed treatment, mPDAC has largely resisted immunotherapeutic approaches—making pelareorep's immune-activating mechanism particularly promising for this underserved patient population. Back in July, Oncolytics hosted a key opinion leader event featuring gastrointestinal cancer experts who reviewed survival outcomes for patients and biomarker validation. The expert panel reinforced the view that pelareorep's mechanism of activating innate and adaptive immune responses is both biologically sound and commercially relevant for first-line mPDAC treatment. With this latest milestone, Oncolytics is entering a phase where FDA feedback will shape both clinical plans and potential commercial partnerships. If the agency accepts the company's proposed trial framework centered on an overall survival endpoint, the resulting study could provide definitive proof of pelareorep's market potential in mPDAC. The company expects to provide an updated clinical timeline in Q3 2025, with trial start-up activities potentially beginning as early as Q4 2025. With compelling survival data, regulatory designations in place, and an experienced leadership team driving execution, Oncolytics is positioning pelareorep for a pivotal test in one of oncology's most challenging and underserved markets. In other recent industry developments and happenings in the market include: ProPhase Labs, Inc. (NASDAQ: PRPH) announced it received a U.S. patent for its BE-Smart test that can detect early signs of Barrett's esophageal cancer, a deadly disease that kills most patients because it's usually caught too late. The test works with simple brush and forceps biopsies and achieved over 95% accuracy in clinical testing, potentially allowing doctors to catch this cancer when it's still treatable. "This achievement, coming on the heels of our BE-Smart ™ validation demonstrating greater than a 95% technical success rate and dual compatibility with both brush and forceps biopsies, solidifies our leadership in medical innovation and brings us one step closer to transforming early detection and treatment strategies for this serious condition," said Ted Karkus, CEP of ProPhase. "With this newly issued patent, we believe we are well positioned to accelerate commercialization and broaden clinical access to BE-Smart." ProPhase's breakthrough could save thousands of lives by identifying patients at high risk for esophageal cancer before the disease becomes incurable, representing a major advancement in early cancer detection. IO Biotech, Inc. (NASDAQ: IOBT) recently announced that its experimental cancer vaccine (Cylembio) meaningfully extended the time before advanced melanoma patients got worse, with patients living 19.4 months without disease progression compared to 11 months for those on standard treatment alone. The vaccine works by training the immune system to attack both cancer cells and the cells that help tumors hide from treatment, and it showed particularly strong results in patients whose tumors were PD-L1 negative and unlikely to respond to current immunotherapies. "In this study, we observed a highly encouraging improvement in progression free survival and consistent trend in overall survival in patients treated with Cylembio," said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. "The magnitude and durability of clinical effect observed consistently across subgroups supports our confidence in Cylembio and its potential as a treatment for advanced melanoma patients. We look forward to engaging with the FDA to determine a potential path to approval based on these data." IO Biotech plans to meet with the FDA this fall to discuss approval for this treatment that could become a new standard of care for the deadliest form of skin cancer. Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) reported progress on its experimental breast cancer pill called palazestrant, which is designed to completely block estrogen signals that fuel most breast cancers and is currently being tested in two large Phase 3 trials expected to finish in 2026. "Having achieved regulatory alignment on the selected dose for our pivotal palazestrant program during the second quarter, we are focused on accelerating enrollment in OPERA-01, which is on track for top-line data in the second half of 2026," said Sean P. Bohen, M.D., Ph.D., President and CEO of Olema. "Palazestrant's demonstrated activity and combinability with multiple compounds offers the potential for it to become a best-in-class, backbone endocrine therapy for metastatic breast cancer." The company is also developing OP-3136, a pill that targets a different pathway cancer cells use to grow and spread, with early results expected in 2026. Olema's drugs are designed to work where current treatments fail, potentially offering hope to the thousands of breast cancer patients whose tumors eventually become resistant to existing therapies. PDS Biotechnology Corporation (NASDAQ: PDSB) reported promising results from a colorectal cancer study where its experimental treatment achieved impressive response rates, leading to expansion of the trial to treat more patients with this hard-to-treat cancer. "Our second quarter of 2025 and recent weeks have been a productive period for PDS Biotech, highlighted by the continued progress in our VERSATILE-003 Phase 3 clinical trial," said Frank Bedu-Addo, Ph.D., President and CEO of PDS Biotech. "We look forward to publishing the full data set for this trial later this year, as we continue to progress our VERSATILE-003 trial, the only registrational stage trial specifically targeting HPV16-positive HNSCC patients." The company's lead program targets head and neck cancers caused by HPV, the same virus that is a major cause of cervical cancer, and is currently being tested in the only late-stage trial specifically designed for these patients. PDS Biotech's approach uses its immune-boosting technology to help the body's natural defenses better recognize and destroy cancer cells, potentially offering new hope for patients with limited treatment options. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Vancouver Sun
40 minutes ago
- Vancouver Sun
Indaba Trading makes the leap to bricks-and-mortar retail
Last year the quaint seaside town of Qualicum Beach lost one its most popular home decor shops when the owners relocated out of province. Before they left, they hinted that what would replace their two retail shops within the charming little plaza would not be a disappointment. True to their word, when it was discovered that Indaba Trading bought the two spaces, there was a discernible ripple of excitement throughout the town. While perhaps not a household name, the Indaba brand, a Parksville-based decor wholesaler and online retailer, is sold all over North America and is well known to interior designers — and to those drawn to the brand's easily recognizable, distinctive esthetic. On a recent summer morning, Irene Held and Alison Gillespie, the mother/daughter duo behind Indaba, sat down for a chat over coffee in the sunny courtyard behind their new Indaba Shoppe. Held founded the business as a young mother having recently arrived in Canada from South Africa — hence the name's origin — a Zulu word meaning the gathering of people. The ethos of the business is grounded in an appreciation for the skill and beauty of handcraft. Stay on top of the latest real estate news and home design trends. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Westcoast Homes will soon be in your inbox. Please try again Interested in more newsletters? Browse here. 'Our interest has always been in handcraft,' Held explains. 'Buying in India, it's very much traditional handcraft. We're obsessed with textiles and India is the mecca for textiles. What people don't understand is what we do is not off the shelf. We don't go to India and say we'll buy this, this and this. Everything is custom made and goes to production.' Even the ceramic pieces that they produce in China are handcrafted. 'The people making our product, it's all handmade still,' Gillespie says. 'People think it doesn't meet our brand values but actually these workshops, it's similar to the Indian product, they've been doing it for thousands of years. It's handmade. You think made-in-China is made by machine but it's not true for all types of products.' Indaba's signature style is a seemingly effortless, relaxed elegance — a sense of almost languid informality but with polish. The textiles in Indaba's collections define that sensibility with the decor accessories being a logical trajectory of that esthetic. 'The subtlety and the relaxed feel — that generally is the theme of what our look is,' Held remarks. 'It's very unfussy. We do have interesting details, and we'll throw in a punch of colour or a little bit of whimsy but primarily it's very easy to live with. It's very easy to integrate, and season to season the new designs follow on from where we were before.' Having launched their online retail shop during COVID, making the leap to a bricks-and-mortar location was a natural progression but, as with most things in life, it came down to the right timing. 'We're always just so busy but it was just in our minds,' Gillespie recalls. 'I do think it was a manifestation in a sense that we were ready for the right location when it presented itself. When we saw Faire Living's Instagram post about moving to Calgary we called and asked right away. They were selling the building, and it just happened.' Gillespie notes that even though their products are in shops all over the U.S. and Canada, the Indaba Shoppe allows them to present the full range of the brand in one place. 'A lot of stores carry our products but it's bits and pieces,' she notes. 'It's bringing our products into their esthetic. It's all our products together.' To complement the Indaba brand, Held and Gillespie have opted to include some local and national makers in the shop, such as the beeswax candle maker Little Mill from Shawnigan Lake, Vancouver's home-and-bath brand Well Kept, and candle and body oil maker Merge from Tofino. The shop will also feature one-of-a-kind items that were developed as samples for a season's collection that for whatever reason didn't make it into production. 'They add a bit of an interesting touch there because you never know what's going to be in there, and those items are not available on the website,' she says. With the view to changing things up either seasonally or from a creative vantage, the Indaba Studio, the second space facing out to the plaza's courtyard, will host various events and give the duo the flexibility to feature different collections. 'It leaves us free to develop the concept of how we're going to have the two shops jive together,' Held observes. Gillespie suggests that perhaps it will be kitchen and dining focused at times, but they have decided to launch with the Christmas collection, likely opening sometime in October. With the two shops opening this year, the duo has plans for events in the courtyard in the future. 'We have lots of ideas. It's just a matter of getting them on a schedule and making it happen,' Gillespie says. Stay tuned.
